Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy
/in Dendritic Cells, International PublicationsDendritic cell vaccine as an alternative to opioid analgesia in patients with advanced cervical cancer.
/in Cervical Cancer, Dendritic Cells, International PublicationsDendritic Cell-Based Therapy Using LY6E Peptide with a Putative Role Against Colorectal Cancer
/in Colorectal Cancer, Dendritic Cells, International PublicationsAddition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
/in Brain Tumors in Children, Dendritic Cells, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusFeasibility of dendritic cell-based vaccine against glioblastoma by using cytoplasmic transduction peptide (CTP)-fused protein antigens combined with anti-PD1
/in Dendritic Cells, Glioblastoma, International PublicationsEx vivo pulsed dendritic cell vaccination against cancer
/in Dendritic Cells, International PublicationsAre dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?
/in Dendritic Cells, International Publications, Ovarian CancerCytokine network analysis of immune responses before and after autologous dendritic cell and tumor cell vaccine immunotherapies in a randomized trial
/in Dendritic Cells, International Publications, Malignant Melanoma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer